GlassScriptPhysician profile
Stefano Pacifici
NPI 1609490200
$2,650.71
in general payments reported to CMS, 2019-2025
20 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $724 · 2024: $530 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.65 |
| Education | $373.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.13 | 2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $377.84 | 2023-2025 | Avvigo Guidance System, Rotapro |
| Novartis Pharmaceuticals Corporation | $340.52 | 2024-2025 | |
| Abbott Laboratories | $321.28 | 2023-2025 | Ensite, Mitraclip, Quadra Assura |
| Astrazeneca Pharmaceuticals LP | $274.80 | 2023-2025 | Farxiga, Imfinzi |
| Amgen INC. | $172.99 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.09 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $169.39 | 2025 | Camzyos |
| Shockwave Medical, INC | $105.98 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $78.44 | 2023-2024 | Xarelto |
| Heartflow, INC. | $36.21 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $32.65 | 2025 | |
| Abiomed | $31.88 | 2025 | |
| Lantheus Medical Imaging, INC. | $24.90 | 2023 | Definity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.87 | 2025 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $24.18 | 2023 | Biomonitor |
| Merck Sharp & Dohme LLC | $22.41 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $21.33 | 2024 | Hemosphere |
| Pfizer INC. | $20.13 | 2025 | |
| Teleflex LLC | $15.69 | 2025 | Guideliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefano Pacifici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.